ArticleFrontiers in pharmacology2026
Efficacy and safety of sintilimab combined with histology-specific chemotherapy in advanced NSCLC: a real-world retrospective study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to evaluate whether the clinical efficacy of first-line sintilimab combined with histology-specific chemotherapy (adenocarcinoma [ADC]: pemetrexed/platinum [Pem/Plat]; squamous cell carcinoma [SqCC]: paclitaxel/platinum [Pac/Plat]) differs by histological subtype in advanced non-small cell lung cancer (NSCLC). Methods: This retrospective, real-world study included 210 patients with advanced NSCLC treated between January 2019 and April 2025 (ADC: n = 124; SqCC: n = 86). The primary endpoints were progression-free survival (PFS) and overall survival (OS). Survival data were analyzed using the Kaplan-Meier method and Cox proportional hazards models, with efficacy heterogeneity tested by incorporating an interaction term. Results: In the overall population, sintilimab plus chemotherapy significantly improved both PFS (median PFS: 12.30 vs. 7.30 months, HR = 0.547, Conclusion: In real-world practice, the survival benefit of sintilimab combined with histology-specific chemotherapy is significantly dependent on the histological subtype in advanced NSCLC. Patients with SqCC derived a clear and substantial survival advantage, whereas the benefit for patients with ADC was more limited and influenced by high metastatic burden. These findings suggest that in the immunotherapy era, histological subtyping remains a crucial yet insufficient guide for clinical decision-making, and future strategies should integrate subtype-specific biomarkers for further treatment optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.